Two FDA-approved hypoglossal nerve stimulators. One goal: helping you sleep and breathe better — without CPAP.
Both Inspire and Genio treat obstructive sleep apnea by gently stimulating the hypoglossal nerve — the nerve that controls your tongue. During sleep, mild electrical impulses keep your airway open so you can breathe naturally, without a mask or machine. Dr. Nord is one of the few surgeons who implants both devices and can help determine which option is the best fit for you.
Breath-synchronized, unilateral stimulation
Inspire is a fully implanted two-part system placed in the chest and neck. A small generator (similar to a pacemaker) delivers stimulation to one side of the hypoglossal nerve in sync with your natural breathing pattern throughout the night. You control the device with a small handheld remote — simply turn it on at bedtime and off when you wake up.
New to Inspire? A surgeon’s guide to the Inspire implant for sleep apnea →
Battery-free implant, bilateral stimulation
Genio uses a small, battery-free stimulator implanted under the chin through a single incision. Each night, you attach a lightweight external activation chip under your chin that powers the implant wirelessly and delivers stimulation to both sides of the hypoglossal nerve using a timed on-and-off pattern. You manage settings through a smartphone app.
New to Genio? A surgeon’s guide to the Genio implant for sleep apnea →
Key differences at a glance
| Feature | Inspire | Genio |
|---|---|---|
| FDA Approved | Yes — 2014 | Yes — 2025 |
| How It Stimulates | Unilateral (one side of the nerve) | Bilateral (both sides of the nerve) |
| Implanted Components | 2 parts: pulse generator and stimulation lead | 1 part: small stimulator chip under the chin |
| Incisions | 2 incisions (neck + chest) | 1 incision (under the chin) |
| Implant Battery | Internal battery (~11 years), then outpatient replacement | No implant battery — powered externally each night |
| Daily Use | Turn on with a handheld remote at bedtime | Attach external activation chip + disposable patch nightly; manage via smartphone app |
| Stimulation Pattern | Stimulation is synchronized with your breathing via a built-in sensor, delivering therapy when you inhale | Duty-cycle algorithm delivers stimulation in a timed on-and-off pattern; no internal sensor needed |
| MRI Compatibility | Conditional — Inspire IV & V allow full-body MRI at 1.5T and 3T (Feb 2026 labeling) under scan conditions; the oldest model (3024) is not MRI compatible | Conditional — MR Conditional at 1.5T and 3T with no body region excluded, provided the scan follows the manufacturer’s conditions, including waiting at least eight weeks after surgery and keeping the external chip and patch out of the scanner room |
| Eligible BMI | Up to 40 in FDA labeling (insurers commonly cap at 32–40; Medicare requires under 35) | The approved indication states no BMI limit. The trial enrolled no one above BMI 32, so there is no evidence above that line, and 32 is the ceiling most surgeons and insurers use in practice |
| AHI Range | 15–100 | 15–65 |
| DISE Required? | Yes — must rule out complete concentric collapse (CCC) | Yes in U.S. practice — the approval itself does not require it, but the trial excluded complete concentric collapse (CCC) and FDA did not approve Genio for that pattern, so DISE is used to rule it out. In Europe, Genio is also approved for CCC |
| Typical Procedure Time* | About an hour of actual operating in experienced hands | About an hour of actual operating in experienced hands |
| Clinical Evidence | Implanted in the U.S. since 2014; STAR trial with published five-year outcomes; ADHERE real-world registry (1,800+ patients in published analyses) | DREAM trial (115 patients, 12-month results); FDA premarket approval August 2025; no published real-world or registry data yet |
| Insurance Coverage | Widely covered by most major insurers and Medicare | Coverage growing; check with your insurer |
* Operative times are hard to compare across published sources because they are not all measured the same way — some count only the time actually spent operating, others count the whole time you are in the operating room, and the two differ by roughly an hour. Reported figures also come from trial and teaching settings. In my own practice, both operations typically take about an hour of actual operating; your anatomy and your surgeon’s experience matter far more than which device you choose.
Numbers like these depend on how each trial measured its result and where it drew the line for “success.” What “success” actually means with an implant →
Both devices require a prior trial of CPAP therapy. What does it mean to fail CPAP? Your surgeon will evaluate which option — or whether either option — is right for you based on your anatomy and medical history.
Sleep study, DISE procedure to evaluate airway anatomy, insurance authorization.
Outpatient surgery under general anesthesia. Two small incisions: one below the jaw and one on the chest for the pulse generator. In experienced hands the operation itself usually takes about an hour.*
Most patients go home the same day. Soreness and swelling for 1–2 weeks. Avoid strenuous activity for ~3 weeks. Pain is typically mild and managed with over-the-counter medication.
Device is activated approximately 1 month after surgery. Settings are fine-tuned over subsequent visits and an in-lab titration sleep study.
Sleep study, consultation, and insurance authorization. A drug-induced sleep endoscopy (DISE) is done to check for complete concentric collapse, the one collapse pattern Genio is not approved to treat in the United States.
Outpatient surgery under general anesthesia. A single small incision under the chin. The battery-free stimulator is secured near the hypoglossal nerve. No chest incision, no leads, no tunneling. In experienced hands the operation itself usually takes about an hour.*
Most patients go home the same day. Swelling under the chin for 1–2 weeks. Avoid strenuous activity for ~2 weeks. The single incision is discreetly hidden in the chin fold.
Labeling calls for waiting at least six weeks after surgery before the device is turned on; in the DREAM trial, activation was done at about two months. Settings are adjusted at follow-up visits, and patients can adjust stimulation strength at home through the app.
Every patient's anatomy and needs are different. Dr. Nord will work with you to determine whether Inspire, Genio, or another approach is the best path to better sleep.
Meet Dr. NordThis page is for educational purposes only and does not constitute medical advice. Individual results may vary. Clinical data referenced from published peer-reviewed studies including the Inspire STAR Trial, ADHERE Registry, and Nyxoah DREAM Study. Both Inspire and Genio are FDA-approved devices for the treatment of moderate to severe obstructive sleep apnea in patients who meet specific eligibility criteria. Always consult with your physician to determine the best treatment option for your individual needs.
Both devices are FDA-approved for adults with moderate-to-severe obstructive sleep apnea who cannot tolerate CPAP. Inspire therapy was validated in the STAR trial, published in the New England Journal of Medicine in 2014, with benefit sustained at five years of follow-up. Genio was validated in the BLAST OSA trial, published in the European Respiratory Journal in 2020 — but that study tested an earlier generation of the device. Genio’s U.S. approval rests on the DREAM trial, published in the Journal of Clinical Sleep Medicine in 2025. A third trial, BETTER SLEEP, is often cited for patients with complete concentric collapse; it was terminated after 42 patients and has never been published in a peer-reviewed journal. Eligibility — including apnea-hypopnea index range and body mass index limits — is defined by each device's FDA-approved indications.
At 12 months, participants saw a 68% reduction in apnea-hypopnea index and a 70% reduction in oxygen desaturation events, with improvements in daytime sleepiness and quality of life.
Strollo PJ Jr, Soose RJ, Maurer JT, et al. Upper-airway stimulation for obstructive sleep apnea. N Engl J Med. 2014;370(2):139–149. Read the study on NEJM →In the first published trial of the Genio system, bilateral hypoglossal nerve stimulation produced a median 47% reduction in apnea-hypopnea index at six months, with improvements in oxygenation and sleep-related quality of life. Genio’s U.S. approval rests on the later DREAM trial.
Eastwood PR, Barnes M, MacKay SG, et al. Bilateral hypoglossal nerve stimulation for treatment of adult obstructive sleep apnea. Eur Respir J. 2020;55(1):1901320. Read the study in ERJ →In the trial supporting Genio’s U.S. approval, 63.5% of all 115 implanted participants met the responder standard at 12 months (81.8% of the 88 who completed per protocol).
Woodson BT, Kent DT, Huntley C, et al. Bilateral hypoglossal nerve stimulation for obstructive sleep apnea: a nonrandomized clinical trial. J Clin Sleep Med. 2025;21(11):1883–1891. Read the study in JCSM →Improvements in AHI, oxygenation, and daytime sleepiness were maintained at five years, with durable patient satisfaction and quality-of-life gains in the STAR cohort.
Woodson BT, Strohl KP, Soose RJ, et al. Upper airway stimulation for obstructive sleep apnea: 5-year outcomes. Otolaryngol Head Neck Surg. 2018;159(1):194–202. Read the abstract on PubMed →Each device's AHI range, BMI limits, and anatomic requirements are defined in its FDA approval. These are the authoritative criteria U.S. surgeons use to determine who is a candidate.
Citations are provided for educational reference. This page summarizes published evidence and is not a substitute for a clinical evaluation — candidacy decisions should be made with a qualified sleep surgeon.
I am a paid consultant to Inspire Medical Systems, a clinical investigator for Nyxoah (the maker of Genio), and a member of the clinical events committee for Nyxoah-sponsored trials including ACCCESS. Full disclosures are on my About page.
Neither manufacturer reviewed, funded, or contributed to this comparison.
